PMID- 38267353
OWN - NLM
STAT- MEDLINE
DCOM- 20240401
LR  - 20240410
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 24
IP  - 4
DP  - 2024 Apr
TI  - Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients 
      with Central Nervous System Involvement, a Systematic Review and Meta-analysis.
PG  - e142-e151
LID - S2152-2650(23)02201-2 [pii]
LID - 10.1016/j.clml.2023.12.012 [doi]
AB  - Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment 
      for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients 
      with central nervous system (CNS) lymphoma were excluded in most of the CAR 
      T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell 
      therapy in LBCL patients with CNS involvement. Two reviewers independently 
      searched PubMed and Cochrane Library to identify all published literature 
      associated with United States Food and Drug Administration approved CAR T-cell 
      therapies for LBCL. Patients with CNS LBCL were included. Meta-analysis of 
      proportion was performed to evaluate the overall response (ORR), complete 
      response (CR) for efficacy, and cytokine release syndrome and immune effector 
      cell-associated neurotoxicity syndrome for safety assessment. Nineteen studies 
      were qualified for inclusion with 141 CNS LBCL patients. The ORR and CR rates 
      were 61% and 55% respectively. The median overall survival (OS) was 8.8 months, 
      and the median progression free survival (PFS) was 4.4 months. Severe immune 
      effector cell-associated neurotoxicity syndrome (grade>/=3) were reported in 25% 
      (32/130) patients and severe cytokine release syndrome (grade>/=3) were found in 
      10% (13/124) of the patients. The safety and efficacy of CAR T-cell therapy in 
      CNS LBCL patients appears comparable to patients without CNS involvement.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Elgohary, Ghada
AU  - Elgohary G
AD  - Ain Shams University, Cairo, Egypt.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson 
      University, Philadelphia, PA.
FAU - Gergis, Mia
AU  - Gergis M
AD  - Tufts University, Boston MA.
FAU - Yi, Dongni
AU  - Yi D
AD  - Mayo Clinic, Rochester MN.
FAU - Gergis, Usama
AU  - Gergis U
AD  - Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson 
      University, Philadelphia, PA. Electronic address: usama.gergis@jefferson.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20240112
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Receptors, Chimeric Antigen
MH  - Cytokine Release Syndrome
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - *Lymphoma, Non-Hodgkin
MH  - *Neurotoxicity Syndromes/etiology
MH  - Central Nervous System
MH  - Cell- and Tissue-Based Therapy
MH  - Antigens, CD19
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - CNS lymphoma
OT  - Efficacy
OT  - Large B-cell lymphoma
OT  - Safety
COIS- Disclosure The authors have stated that they have no conflicts of interest.
EDAT- 2024/01/25 00:42
MHDA- 2024/04/01 06:43
CRDT- 2024/01/24 21:57
PHST- 2023/11/02 00:00 [received]
PHST- 2023/12/12 00:00 [revised]
PHST- 2023/12/17 00:00 [accepted]
PHST- 2024/04/01 06:43 [medline]
PHST- 2024/01/25 00:42 [pubmed]
PHST- 2024/01/24 21:57 [entrez]
AID - S2152-2650(23)02201-2 [pii]
AID - 10.1016/j.clml.2023.12.012 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e142-e151. doi: 
      10.1016/j.clml.2023.12.012. Epub 2024 Jan 12.